Jeffrey Epstein was not a myth, but a ruthless sex offender who, over years, spun a web of abuse, manipulation, and abuse of power. His actions destroyed the lives of numerous young women and girls. Yet, while the victims still hope for justice today, the Trump administration has done everything to obscure the full truth and block the investigation. The cries of the victims – and the silence of the powerful Epstein's victims report systematic abuse, psychological violence, and a perfidious system that supplied young girls to rich and influential men. Many of them were minors, some barely older than 14. They speak of fear, shame, and lifelong trauma – and how they were ignored or even intimidated by authorities and the justice system for a long time. "I was used, sold, and silenced," says one of the victims. "For years, no one listened." Trump administration: Cover-up instead of… 

Beijing, July 7, 2025 – A groundbreaking advance in biotechnology could fundamentally change the way proteins are developed for medical and industrial applications. A team of Chinese scientists led by Prof. Gao Caixia from the Institute of Genetics and Developmental Biology (IGDB) of the Chinese Academy of Sciences has developed a novel method called “AI-informed Constraints for Protein-Engineering” (AiCE). This AI-powered strategy, published on July 7, 2025, in the renowned journal Cell, promises to make protein engineering more efficient, cost-effective, and universally applicable. The approach uses inverse folding models and considers structural and evolutionary constraints without requiring specialized AI models to be trained. Challenges of Protein Engineering Proteins are the molecular workhorses of life and play a central role in biological processes, from immune defense to energy production. Their targeted modification, known as protein engineering, is crucial for the development… 

Tampa General Hospital (TGH) and USF Health have achieved a medical milestone: the world's first documented bloodless heart-liver transplant. The groundbreaking surgery was led by Dr. Kiran Dhanireddy and Dr. Gundars Katlaps, both leading experts at the TGH Transplant Institute and USF Health Morsani College of Medicine. The patient, who suffered from coronary heart disease and fatty liver disease, waited over 18 months for this complex double organ transplant, which had to be performed without blood products – a rare and technically demanding feat. “The surgery demonstrates the strength of academic medicine,” emphasized Dhanireddy. “Our expertise and multidisciplinary collaboration enable the best outcomes for patients.” TGH, the nation's leading transplant center with 889 procedures in 2024, is setting new standards in bloodless surgery. This method, which began in 1986 with the first bloodless single organ transplant, offers benefits such as faster recovery and a lower risk of infection. “No patient should be denied… 

Calidi Biotherapeutics Inc. (NYSE American: CLDI) has developed an innovative technology platform that enables the systemic delivery of genetic medicines to tumor sites, including metastatic cancers. The platform utilizes proprietary, genetically engineered oncolytic viruses that hide therapeutic payloads within a protective human cell membrane to evade the immune system and specifically target metastases. Lead Product CLD-401 Shows Promising Results The lead product, CLD-401, delivers the IL-15 superagonist directly to tumor sites, demonstrating impressive results in preclinical studies for tumor eradication and immune activation. The technology allows for intravenous administration, enabling genetic payloads to reach tumors throughout the body. Preclinical data, presented at the American Association of Cancer Research (AACR) and American Association of Clinical Oncology (ASCO) conferences in 2025, show that CLD-401 can destroy tumors and activate the immune system to prevent recurrence. Future Plans and Market Development Calidi plans to submit an Investigational New Drug (IND) application by the end of 2026…